AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:XLY - CA05335P1099 - Common Stock
0.155 CAD
0 (0%)
We assign a fundamental rating of 5 out of 10 to XLY. XLY was compared to 32 industry peers in the Pharmaceuticals industry. While XLY is still in line with the averages on profitability rating, there are concerns on its financial health. XLY is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year XLY was profitable.
In the past year XLY had a positive cash flow from operations.
In the past 5 years XLY always reported negative net income.
In multiple years XLY reported negative operating cash flow during the last 5 years.
1.2 Ratios
XLY's Return On Assets of 10.86% is amongst the best of the industry. XLY outperforms 93.75% of its industry peers.
The Return On Equity of XLY (20.44%) is better than 96.88% of its industry peers.
XLY has a Return On Invested Capital of 6.44%. This is amongst the best in the industry. XLY outperforms 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.86% | ||
| ROE | 20.44% | ||
| ROIC | 6.44% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 20.15%, XLY belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
Looking at the Operating Margin, with a value of 9.65%, XLY is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
The Gross Margin of XLY (43.74%) is better than 62.50% of its industry peers.
XLY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.65% | ||
| PM (TTM) | 20.15% | ||
| GM | 43.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XLY is destroying value.
The number of shares outstanding for XLY has been increased compared to 1 year ago.
The number of shares outstanding for XLY has been increased compared to 5 years ago.
Compared to 1 year ago, XLY has an improved debt to assets ratio.
2.2 Solvency
XLY has an Altman-Z score of -0.74. This is a bad value and indicates that XLY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.74, XLY is in line with its industry, outperforming 43.75% of the companies in the same industry.
The Debt to FCF ratio of XLY is 3.08, which is a good value as it means it would take XLY, 3.08 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.08, XLY belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
XLY has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, XLY is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 3.08 | ||
| Altman-Z | -0.74 |
ROIC/WACC0.83
WACC7.8%
2.3 Liquidity
XLY has a Current Ratio of 0.76. This is a bad value and indicates that XLY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of XLY (0.76) is worse than 90.63% of its industry peers.
A Quick Ratio of 0.39 indicates that XLY may have some problems paying its short term obligations.
With a Quick ratio value of 0.39, XLY is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.39 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 151.10% over the past year.
The Revenue has grown by 21.02% in the past year. This is a very strong growth!
Measured over the past years, XLY shows a very strong growth in Revenue. The Revenue has been growing by 71.07% on average per year.
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)21.02%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
XLY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.57% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.98%
Revenue Next 2Y26.62%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
XLY is valuated cheaply with a Price/Earnings ratio of 3.88.
Based on the Price/Earnings ratio, XLY is valued cheaply inside the industry as 96.88% of the companies are valued more expensively.
XLY is valuated cheaply when we compare the Price/Earnings ratio to 26.41, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.88 | ||
| Fwd PE | N/A |
4.2 Price Multiples
XLY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. XLY is cheaper than 62.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, XLY is valued a bit cheaper than the industry average as 71.88% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.46 | ||
| EV/EBITDA | 10.56 |
4.3 Compensation for Growth
XLY has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for XLY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:XLY (12/4/2025, 7:00:00 PM)
0.155
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners4.71%
Ins Owner ChangeN/A
Market Cap209.01M
Revenue(TTM)122.33M
Net Income(TTM)28.08M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.88 | ||
| Fwd PE | N/A | ||
| P/S | 1.5 | ||
| P/FCF | 10.46 | ||
| P/OCF | 9.64 | ||
| P/B | 1.52 | ||
| P/tB | 1.93 | ||
| EV/EBITDA | 10.56 |
EPS(TTM)0.04
EY25.81%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY9.56%
OCF(TTM)0.02
OCFY10.38%
SpS0.1
BVpS0.1
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.86% | ||
| ROE | 20.44% | ||
| ROCE | 8.94% | ||
| ROIC | 6.44% | ||
| ROICexc | 7.27% | ||
| ROICexgc | 9.29% | ||
| OM | 9.65% | ||
| PM (TTM) | 20.15% | ||
| GM | 43.74% | ||
| FCFM | 14.33% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 3.08 | ||
| Debt/EBITDA | 0.54 | ||
| Cap/Depr | 16.21% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.4% | ||
| Profit Quality | 71.14% | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.39 | ||
| Altman-Z | -0.74 |
F-Score6
WACC7.8%
ROIC/WACC0.83
Cap/Depr(3y)27.93%
Cap/Depr(5y)61.49%
Cap/Sales(3y)4.52%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21.02%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
Revenue Next Year18.98%
Revenue Next 2Y26.62%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
EBIT growth 1Y140.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year399.98%
EBIT Next 3Y106.86%
EBIT Next 5Y66%
FCF growth 1Y357.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3342.22%
OCF growth 3YN/A
OCF growth 5YN/A
AUXLY CANNABIS GROUP INC / XLY.CA FAQ
What is the ChartMill fundamental rating of AUXLY CANNABIS GROUP INC (XLY.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to XLY.CA.
What is the valuation status for XLY stock?
ChartMill assigns a valuation rating of 5 / 10 to AUXLY CANNABIS GROUP INC (XLY.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for AUXLY CANNABIS GROUP INC?
AUXLY CANNABIS GROUP INC (XLY.CA) has a profitability rating of 6 / 10.